Iridex Stock (NASDAQ:IRIX), Trade Ideas

Iridex

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Federal Reserve

Intraday Update

Markets

Trading Ideas

CLLS

IRIX

PATI

PAYC

TGTX

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision.

The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&amp;P 500 also rose, gaining, 0.67% to 4,221.94.

Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged

Movers

ALDX

ASTE

BALY

BGFV

CHEF

CNDT

CWBR

DTCK

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXTR

FTDR

GDEV

GNRC

GOOS

GRMN

GTHX

Kintara Therapeutics, Inc. - Common Stock

KTRA

LIFW

LUMN

MNPR

MOTS

Merrill Lynch & Strategic Return Notes for Select 10 Index

MTCH

NMRK

PCTY

PIXY

PSTV

PUYI

SIEN

SITE

SLAB

SPWR

SYNA

TMPO

TNXP

TRTX

YUMC

ZVSA

Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The S&amp;P 500 also rose, gaining, 0.74% to 4,224.85.

Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge

IRIDEX Corp

<h3>Gainers</h3>
<ul>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market cap stands at $39.3 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 37.85% to $0.08. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock rose 12.19% to $0.55. The company's market cap stands at $54.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 9.36% to $1.2. The company's market cap stands at $33.0 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 8.73% to $1.12. The market value of their outstanding shares is at $19.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares increased by 8.62% to $17.12. The company's market cap stands at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 12.6% to $4.22 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) stock declined by 12.31% to $0.57. The market value of their outstanding shares is at $92.3 million. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock decreased by 11.37% to $7.72. The company's market cap stands at $425.2 million. The company's, Q4 earnings came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 9.27% to $1.47. The market value of their outstanding shares is at $6.2 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 8.89% to $0.41. The company's market cap stands at $18.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock decreased by 8.28% to $2.77. The company's market cap stands at $45.0 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DARE

PHGE

PLSE

RNAC

SBFM

TLPH

VVOS

ZNTL

12 Health Care Stocks Moving In Thursday's After-Market Session

WIIM

IRIDEX shares are trading higher. The company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 5.52% to $2.65. The company's market cap stands at $43.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 22.9% to $0.29 during Tuesday's after-market session. The company's market cap stands at $23.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock fell 11.34% to $1.02. The company's market cap stands at $15.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 9.84% to $1.1. The market value of their outstanding shares is at $40.2 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 7.21% to $3.6. The market value of their outstanding shares is at $4.2 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares declined by 7.21% to $230.0. The company's market cap stands at $10.8 billion. </li>
<li>ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) stock decreased by 6.46% to $0.58. The market value of their outstanding shares is at $10.0 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

APLM

BSGM

CARA

COEP

ESLA

MIRA

TTNP

UTHR

VRPX

12 Health Care Stocks Moving In Tuesday's After-Market Session

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Iridex missed estimated earnings by -260.0%, reporting an EPS of $-0.18 versus an estimate of $-0.05.
Revenue was down $2.74 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 7.000000000000001% increase in the share price the next day.
Here's a look at Iridex's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>13.48M</td>
<td>14.23M</td>
<td>13.64M</td>
<td>15.16M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.85M</td>
<td>12.86M</td>
<td>13.71M</td>
<td>15.20M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Iridex <a href="https://www.benzinga.com/quote/IRIX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Iridex: Q4 Earnings Insights

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.05) by 260 percent. The company reported quarterly sales of $12.458 million which missed the analyst consensus estimate of $14.900 million by 16.39 percent. This is a 18.01 percent decrease over sales of $15.195 million the same period last year.

Earnings Misses

Iridex Q4 2023 GAAP EPS $(0.18) Misses $(0.05) Estimate, Sales $12.458M Miss $14.900M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
&bull; AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report earnings for its fourth quarter.
&bull; Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion.
&bull; GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million.
&bull; Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report earnings for its fourth quarter.
&bull; Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is likely to report quarterly loss at $0.04 per share on revenue of $148.11 million.
&bull; DouYu Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $170.91 million.
&bull; Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $94.55 million.
&bull; Forza X1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) is likely to report earnings for its fourth quarter.
&bull; Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is likely to report earnings for its fourth quarter.
&bull; Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is likely to report earnings for its fourth quarter.
&bull; Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is expected to report quarterly loss at $0.51 per share on revenue of $540 thousand.
&bull; Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) is estimated to report earnings for its fourth quarter.
&bull; Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $174.80 million.
&bull; Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is estimated to report earnings for its fourth quarter.
&bull; McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $1.56 billion.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report earnings for its first quarter.
&bull; TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.84 per share on revenue of $14.36 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is estimated to report earnings for its fourth quarter.
&bull; Marpai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) is estimated to report earnings for its fourth quarter.
&bull; NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) is likely to report quarterly loss at $0.30 per share on revenue of $3.40 million.
&bull; Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) is projected to report earnings for its fourth quarter.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.87 million.
&bull; X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) is likely to report earnings for its fourth quarter.
&bull; Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $14.90 million.
&bull; iPath Series B Carbon Exchange-Traded Notes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRN#NYSE">GRN</a>) is projected to report quarterly loss at $0.01 per share on revenue of $13.40 million.
&bull; Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.64 million.
&bull; BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter.
&bull; GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $2.05 billion.
&bull; Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.10 per share on revenue of $19.57 million.
&bull; Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) is expected to report earnings for its fourth quarter.
&bull; ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) is expected to report quarterly loss at $0.31 per share on revenue of $7.37 million.
&bull; ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) is likely to report earnings for its fourth quarter.
&bull; Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its fourth quarter.
&bull; PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) is projected to report quarterly loss at $1.89 per share on revenue of $1.05 million.
&bull; AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) is likely to report quarterly loss at $1.20 per share on revenue of $100 thousand.
&bull; Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) is likely to report quarterly loss at $0.08 per share on revenue of $19.50 million.
&bull; Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is expected to report quarterly earnings at $1.14 per share on revenue of $181.91 million.
&bull; WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) is estimated to report earnings for its fourth quarter.
&bull; LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $34.20 million.
&bull; Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is expected to report earnings for its fourth quarter.
&bull; Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $2.58 per share on revenue of $2.38 billion.
&bull; Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) is likely to report quarterly loss at $0.83 per share on revenue of $24.06 million.
&bull; Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $124.62 million.
&bull; PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $12.62 million.
&bull; Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $18.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AACG

ABOS

APTO

BCAB

BIOR

BLRX

BLUE

BRAG

CGTX

CNXC

DCTH

DOYU

DRCT

ESLT

FRGE

FRZA

INTZ

KSPI

LIDR

LUXH

MRAI

NCNO

NOAH

OUST

OXBR

PAVM

PAYS

PRGS

RVYL

SIDU

SOAR

USEG

VEEE

Earnings Scheduled For March 26, 2024

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement.
Analysts estimate that Iridex will report an earnings per share (EPS) of $-0.05. 
Iridex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 6.84% increase in the share price the next day.
Here's a look at Iridex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-28.000000000000004%</td>
<td>-0.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711382446_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Iridex were trading at $2.56 as of March 22. Over the last 52-week period, shares are up 28.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IRIX/earnings">To track all earnings releases for Iridex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Iridex's Earnings Outlook

Iridex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use". This groundbreaking patent further protects Iridex's intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse&#xAE; devices that utilize the patented technology.&nbsp;&nbsp;
Revolutionizing Eye Care with Precision and Safety The patented technology delivers a state-of-the-art laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond. By employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.
Overcoming Limitations of Current Technologies This innovative MicroPulse technology addresses the limitations of current continuous wave visible lasers. It incorporates advanced software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The system's ability to produce controlled-width pulse trains with reduced power fluctuations represents a novel leap forward in medical laser technology. This technology covers the full laser wavelength range from 520nm-615 nm. In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.
A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.

Biotech

General

Iridex Corporation Receives European Patent On MicroPulse Technology EP 3009093, Entitled "Laser System With Short Pulse Characteristics And Its Methods Of Use"

Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse&#xAE; Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6&#xAE; Laser and the MicroPulse P3&#xAE; Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. &nbsp;
David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicenter participation enabling a large-scale view and significant in-country impact of our MicroPulse&#xAE; technology."
The study, titled "MicroPulse Transscleral Laser Therapy: A Prospective UK Study," is set to expand Iridex's global clinical portfolio, through its commitment to funding essential components of the 3-year study and providing a custom-designed and secure database management system.
Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasized the importance of rapid expansion: "We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma.&nbsp;Expansion to include other units will be crucial in advancing glaucoma treatment in the UK.&nbsp;Our partnership with Iridex is key to enhancing this study's reach and impact."&nbsp;
The Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulse&#xAE; TLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.
Both Iridex and Imperial College Healthcare NHS Trust are dedicated to conducting this study in accordance with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program. The collaboration symbolizes the company's shared vision for advancing medical science with MicroPulse&#xAE; TLT. It promises significant insights and advancements in glaucoma laser therapy, potentially revolutionizing treatment approaches and enhancing patient care.
Iridex would like to thank and acknowledge Carleton Optical Equipment Ltd, located in Chesham, England, for providing clinical trial training, service, and support.

Iridex Announces First Patient Enrollment In MicroPulse TLT Clinical Study Conducted In Collaboration With Imperial College Healthcare NHS Trust

Iridex To Showcase New 532® And 577® Laser Technologies At Hawaiian Eye And Retina 2024 Meeting

Iridex Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irix#NASDAQ">IRIX</a>), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors ("MACs") retired their local coverage determinations ("LCDs") that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate for continued patient access to clinically proven safe and effective glaucoma treatments. The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products.

Iridex Says All Five Medicare Administrative Contractors Retired Their Local Coverage Determinations That Were Scheduled To Take Effect On January 29, 2024

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $12.85 million which missed the analyst consensus estimate of $13.48 million by 4.67 percent. This is a 12.20 percent decrease over sales of $14.63 million the same period last year.

Earnings Beats

Iridex Q3 EPS $(0.11) Beats $(0.12) Estimate, Sales $12.85M Miss $13.48M Estimate

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported its Q3 earnings results on Tuesday, November 14, 2023 at 04:21 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Iridex beat estimated earnings by 8.33%, reporting an EPS of $-0.11 versus an estimate of $-0.12.
Revenue was down $1.78 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.06 which was followed by a 28.25% drop in the share price the next day.
Here's a look at Iridex's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.07</td>
<td>-0.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>14.23M</td>
<td>13.64M</td>
<td>15.16M</td>
<td>13.87M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.86M</td>
<td>13.71M</td>
<td>15.20M</td>
<td>14.63M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Iridex <a href="https://www.benzinga.com/quote/IRIX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Iridex: Q3 Earnings Insights

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision.
The Dow traded up 0.40% to 33,185.41&nbsp;while the NASDAQ rose 0.92% to 12,969.54. The S&amp;P 500 also rose, gaining, 0.67% to 4,221.94.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35508877/2-8m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying"> $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
Information technology shares jumped by 1.2% on Wednesday.
In trading on Wednesday, materials shares fell by 0.6%.
&nbsp;
<h3>Top Headline</h3>
The Federal Reserve opted to maintain interest rates at the range of&nbsp;5.25%&nbsp;to&nbsp;5.5%&nbsp;during its November meeting, as widely&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/23/11/35545457/no-rate-hike-fed-maintains-interest-rates-at-5-25-5-5-keeps-future-options-open">anticipated by the market</a>.
&nbsp;
<h3>Equities Trading UP</h3>
Cellectis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>) shares shot up 194% to $2.8335. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.
Shares of Patriot Transportation Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pati#NASDAQ">PATI</a>) got a boost, shooting 103% to $15.59. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash.
TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) shares were also up, gaining 32% to $10.18 following third-quarter results.
&nbsp;
<h3>Equities Trading DOWN</h3>
WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) shares dropped 51% to $1.1150 following reports that the company is nearing bankruptcy.
Shares of IRIDEX Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irix#NASDAQ">IRIX</a>) were down 38% to $2.0425. Iridex has withdrawn its previously announced annual guidance for 2023 and plans to provide additional information during its third-quarter earnings release based on the information available at that time.
Paycom Software, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/payc#NYSE">PAYC</a>) was down, falling 39% to $150.30. Paycom Software reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35510705/top-3-consumer-stocks-that-could-sink-your-portfolio-in-q4"> Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4</a>
&nbsp;
<h3>Commodities</h3>
In commodity news, oil traded down 0.1% to $80.91 while gold traded down 0.3% at $1,986.90.
Silver traded down 0.5% to $22.835 on Wednesday while copper fell 0.1% to $3.6450.
&nbsp;
<h3>Euro zone</h3>
European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.67%, London&rsquo;s FTSE 100 rose 0.28% while Spain&rsquo;s IBEX 35 Index rose 0.64% The German DAX gained 0.76% French CAC 40 climbed 0.68%, while Italy&rsquo;s FTSE MIB Index jumped 0.88%.
The S&amp;P Global/CIPS UK manufacturing PMI was revised lower to 44.8 in October from the preliminary reading of 45.2, while Nationwide House Price Index fell by 3.3% year-over-year in October.
&nbsp;
<h3>Asia Pacific Markets</h3>
Asian markets closed mixed on Wednesday, with Japan&rsquo;s Nikkei 225 rising 2.41%, Hong Kong&rsquo;s Hang Seng Index falling 0.06% and China&rsquo;s Shanghai Composite Index gaining 0.14%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, slipped around 0.4%.
Retail sales in Hong Kong surged 10.1% year-over-year in September versus a 11% increase in the prior month. The S&amp;P Global India manufacturing PMI fell to 55.5 in October from 57.5, while the Caixin China general manufacturing PMI declined to 49.5 in October from 50.6 in the previous month. The au Jibun Bank Japan manufacturing PMI was revised higher to 48.7 in October.
&nbsp;
<h3>Economics</h3>
Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.
Construction spending in the U.S. increased by 0.4% month-over-month to an annual rate of $1,996.5 billion in September.
The number of job openings rose by 56,000 from the prior month to 9.55 million in September.
The S&amp;P Global manufacturing PMI rose to 50.0 in October from 49.8 in September.
The ISM Manufacturing PMI fell to 46.7 in October versus 49 in the prior month, compared to market expectations of 49.
U.S. crude oil inventories increased by 0.774 million barrels in the week ending Oct. 27, 2023, compared to a 1.371 million rise in the prior period and versus market estimates of a 1.261 million increase.
The Federal Reserve left the key interest rate unchanged at the range of&nbsp;5.25%&nbsp;to&nbsp;5.5%&nbsp;on Wednesday.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35509384/these-3-real-estate-stocks-delivering-high-dividend-yields-are-recommended-by-wall-stree"> These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>

<h3>Gainers</h3>
<ul>
<li>Cellectis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>) shares jumped 136% to $2.2799. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.</li>
<li>Patriot Transportation Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pati#NASDAQ">PATI</a>) climbed 104.8% to $15.73. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash.</li>
<li>Aldeyra Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aldx#NASDAQ">ALDX</a>) gained 33% to $2.2780. Aldeyra Therapeutics entered into an exclusive option agreement with AbbVie Inc.</li>
<li>ShiftPixy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pixy#NASDAQ">PIXY</a>) climbed 30% to $6.82.</li>
<li>Monopar Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnpr#NASDAQ">MNPR</a>) shares rose 29% to $0.5782. Monopar presented data showing tumor reduction benefit of camsirubicin from ongoing Phase 1b in patients with advanced soft tissue sarcoma at the 2023 Connective Tissue Oncology Society Annual Meeting.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) climbed 26.8% to $9.80 following third-quarter results.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) gained 25% to $3.08. On Monday, the company announced that it is in compliance with all applicable Nasdaq listing standards.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) climbed 20% to $0.0984. ZyVersa Therapeutics announced publication in molecular neurobiology reinforcing data demonstrating that inflammasome ASC inhibitor IC 100 attenuates the inflammatory response causing neuronal damage in multiple sclerosis model.</li>
<li>EUDA Health Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/euda#NASDAQ">EUDA</a>) rose 18.6% to $1.02.</li>
<li>GDEV Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdev#NASDAQ">GDEV</a>) shares gained 16.2% to $2.35 after falling 11% on Tuesday.</li>
<li>Maison Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mss#NASDAQ">MSS</a>) climbed 14.5% to $6.31.</li>
<li>Generac Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gnrc#NYSE">GNRC</a>) gained 13.7% to $95.60 following upbeat earnings.</li>
<li>Mercury General Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcy#NYSE">MCY</a>) gained 13.5% to $35.04 following quarterly results.</li>
<li>Davis Commodities Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtck#NASDAQ">DTCK</a>) rose 13.4% to $4.1850.</li>
<li>Newmark Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmrk#NASDAQ">NMRK</a>) gained 13.4% to $6.44 following strong quarterly results.</li>
<li>The Scotts Miracle-Gro Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>) rose 11.8% to $49.70 following upbeat results.</li>
<li>Mercurity Fintech Holding Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NYSE">MFH</a>) surged 11.4% to $0.9950.</li>
<li>Garmin Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grmn#NYSE">GRMN</a>) gained 10.4% to $113.16 after the company posted upbeat third-quarter results and raised FY23 guidance.</li>
<li>Frontdoor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftdr#NASDAQ">FTDR</a>) climbed 10.2% to $31.89 following strong results.</li>
<li>Assurant, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aiz#NYSE">AIZ</a>) rose 10.2% to $164.09 following third quarter results.</li>
<li>Sientra, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sien#NASDAQ">SIEN</a>) shares climbed 10.1% to $0.7049. Sientra shares fell 56% on Tuesday after the company withdrew its FY23 guidance and reported interim third-quarter financial results.</li>
<li>Apollo Global Management, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apo#NYSE">APO</a>) gained 10% to $85.17 after reporting third-quarter results.</li>
<li>Plus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pstv#NASDAQ">PSTV</a>) shares rose 9% to $1.34 after the company reported third-quarter financial results and announced a share repurchase program.</li>
<li>The Chefs&#39; Warehouse, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chef#NASDAQ">CHEF</a>) gained 9% to $20.74 following strong sales.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) shares dipped 51.5% to $1.1050 following reports that the company is nearing bankruptcy.</li>
<li>CohBar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cwbr#NASDAQ">CWBR</a>) fell 48.2% to $0.91. CohBar said on Nov. 1, it got termination notice from Morphogenesis, effective Nov. 1 and merger agreement was terminated in accordance with terms.</li>
<li>IRIDEX Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irix#NASDAQ">IRIX</a>) fell 44.2% to $1.83. Iridex has withdrawn its previously announced annual guidance for 2023 and plans to provide additional information during its third-quarter earnings release based on the information available at that time.</li>
<li>Tempo Automation Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmpo#NASDAQ">TMPO</a>) shares fell 37.8% to $0.0516 after dipping 30% on Tuesday.</li>
<li>Paycom Software, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/payc#NYSE">PAYC</a>) fell 37.2% to $153.96. Paycom Software reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) fell 30% to $0.5205.</li>
<li>MasTec, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtz#NYSE">MTZ</a>) fell 23.2% to $45.63 following weak sales.</li>
<li>Lumen Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lumn#NYSE">LUMN</a>) dipped 23.2% to $1.1200 following weak earnings.</li>
<li>Astec Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aste#NASDAQ">ASTE</a>) declined 21.6% to $31.40 following downbeat results.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) fell 22% to $0.4678. Motus GI said 1-for-15 reverse stock split, will begin trading on split-adjusted basis Nov. 2.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) dipped 20.5% to $102.35 following its first quarter results and lackluster outlook.</li>
<li>G1 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gthx#NASDAQ">GTHX</a>) fell 18.8% to $1.3397 following weak results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnxp#NASDAQ">TNXP</a>) shares fell 18.2% to $0.4825 after the company reported topline results from Phase 2 proof-of-concept study of TNX-601 ER for the treatment of major depressive disorder.</li>
<li>Conduent Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cndt#NASDAQ">CNDT</a>) dropped 17% to $2.6490 following weak earnings.</li>
<li>Yum China Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yumc#NYSE">YUMC</a>) shares fell 16.9% to $43.67 after the company reported worse-than-expected financial results for its third quarter.</li>
<li>Match Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtch#NASDAQ">MTCH</a>) declined 16.2% to $29.00 after reporting third-quarter results and issuing fourth-quarter guidance.</li>
<li>Big 5 Sporting Goods Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgfv#NASDAQ">BGFV</a>) shares fell 14.6% to $6.02 after the company reported weaker-than-expected results for its third quarter.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) dipped 14.6% to $17.62 after the company reported first-quarter financial results and issued second-quarter guidance below estimates.</li>
<li>Bally&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baly#NYSE">BALY</a>) fell 14.4% to $7.81 following downbeat results.</li>
<li>Silicon Laboratories Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slab#NASDAQ">SLAB</a>) fell 14.2% to $79.13 after the company reported third quarter financial results and issued fourth-quarter guidance.</li>
<li>Fresh Del Monte Produce Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdp#NYSE">FDP</a>) declined 13.3% to $21.67 following downbeat results.</li>
<li>Puyi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/puyi#NASDAQ">PUYI</a>) fell 12.7% to $6.29.</li>
<li>TPG RE Finance Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trtx#NYSE">TRTX</a>) declined 12.3% to $4.83 following weak results.</li>
<li>SunCoke Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sxc#NYSE">SXC</a>) fell 11.7% to $8.40 following third-quarter results.</li>
<li>Paylocity Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcty#NASDAQ">PCTY</a>) dropped 10% to $161.41.</li>
<li>Canada Goose Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/goos#NYSE">GOOS</a>) dipped 10% to $9.99 following quarterly results.</li>
<li>SiteOne Landscape Supply, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/site#NYSE">SITE</a>) fell 9.7% to $124.32 following weak earnings.</li>
<li>Unum Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unm#NYSE">UNM</a>) fell 8.3% to $44.82 following weak sales.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) fell 7.8% to $3.9350 following quarterly results.</li>
<li>BAIYU Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/byu#NASDAQ">BYU</a>) fell 7.7% to $1.9201 after dipping 19% on Tuesday.</li>
<li>Synaptics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/syna#NASDAQ">SYNA</a>) fell 7% to $77.90.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/11/35537627/ethereum-falls-below-1-800-following-adp-report-gala-becomes-top-loser"> Ethereum Falls Below $1,800 Following ADP Report; Gala Becomes Top Loser</a>

Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) shares moved upwards by 188.6% to $2.8 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 58.7 million, which is 110697.6% of its average full-day volume over the last 100 days. The company's market cap stands at $155.6 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares rose 50.74% to $2.58. Aldeyra Therapeutics's stock is trading at a volume of 58.1 million shares as of 13:31 EST. This is 5356.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $151.0 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock increased by 37.51% to $0.59. As of 13:31 EST, this security is trading at a volume of 47.8 million shares, making up 32194.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.3 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) shares rose 31.95% to $10.2. The current volume of 41.9 million shares is 796.4% of TG Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $1.5 billion. The company's, Q3 earnings came out today. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) stock moved upwards by 30.59% to $8.75. The current volume of 87.0K shares is 136.0% of Silence Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $321.5 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares rose 25.4% to $0.39. Trading volume for this security as of 13:31 EST is 2.6 million, which is 249.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CohBar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBR#NASDAQ">CWBR</a>) stock declined by 48.9% to $0.92 during Wednesday's regular session. As of 13:31 EST, this security is trading at a volume of 255.6K shares, making up 1693.3% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock decreased by 34.61% to $2.15. Iridex's stock is trading at a volume of 1.6 million shares as of 13:31 EST. This is 1965.2% of its average full-day volume over the last 100 days. The company's market cap stands at $34.8 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock fell 33.25% to $0.51. The current volume of 1.8 million shares is 3306.6% of Kintara Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares declined by 25.99% to $0.1. Tenon Medical's stock is trading at a volume of 846.1K shares as of 13:31 EST. This is 61.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.3 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock declined by 19.39% to $1.33. G1 Therapeutics's stock is trading at a volume of 836.8K shares as of 13:31 EST. This is 109.4% of its average full-day volume over the last 100 days. The company's market cap stands at $68.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Stevanato Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) shares declined by 16.37% to $23.38. The current volume of 588.4K shares is 173.4% of Stevanato Gr's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $6.9 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTIL

STVN

TNON

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
The Dow traded up 0.55% to 33,233.33 while the NASDAQ rose 0.87% to 12,962.92. The S&amp;P 500 also rose, gaining, 0.74% to 4,224.85.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35508877/2-8m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying"> $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares jumped by 1.3% on Wednesday.
In trading on Wednesday, utilities shares fell by 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The ISM manufacturing PMI fell to 46.7 in October versus 49 in the prior month, compared to market expectations of 49.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Cellectis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>) shares shot up 148% to $2.3910. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.
Shares of Patriot Transportation Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pati#NASDAQ">PATI</a>) got a boost, shooting 104% to $15.69. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash.
TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) shares were also up, gaining 29% to $9.98 following third-quarter results.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) shares dropped 52% to $1.09 following reports that the company is nearing bankruptcy.
Shares of IRIDEX Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irix#NASDAQ">IRIX</a>) were down 43% to $1.8669. Iridex has withdrawn its previously announced annual guidance for 2023 and plans to provide additional information during its third-quarter earnings release based on the information available at that time.
Paycom Software, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/payc#NYSE">PAYC</a>) was down, falling 38% to $153.11. Paycom Software reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35510705/top-3-consumer-stocks-that-could-sink-your-portfolio-in-q4"> Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 2.2% to $82.81 while gold traded up 0.3% at $1,999.60.
Silver traded up 0.4% to $23.052 on Wednesday while copper rose 1% to $3.6850.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.73%, London&rsquo;s FTSE 100 rose 0.65% while Spain&rsquo;s IBEX 35 Index rose 0.65% The German DAX gained 0.69% French CAC 40 climbed 0.68%, while Italy&rsquo;s FTSE MIB Index jumped 0.99%.
The S&amp;P Global/CIPS UK manufacturing PMI was revised lower to 44.8 in October from the preliminary reading of 45.2, while Nationwide House Price Index fell by 3.3% year-over-year in October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Wednesday, with Japan&rsquo;s Nikkei 225 rising 2.41%, Hong Kong&rsquo;s Hang Seng Index falling 0.06% and China&rsquo;s Shanghai Composite Index gaining 0.14%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, slipped around 0.4%.
Retail sales in Hong Kong surged 10.1% year-over-year in September versus a 11% increase in the prior month. The S&amp;P Global India manufacturing PMI fell to 55.5 in October from 57.5, while the Caixin China general manufacturing PMI declined to 49.5 in October from 50.6 in the previous month. The au Jibun Bank Japan manufacturing PMI was revised higher to 48.7 in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.
Construction spending in the U.S. increased by 0.4% month-over-month to an annual rate of $1,996.5 billion in September.
The number of job openings rose by 56,000 from the prior month to 9.55 million in September.
The S&amp;P Global manufacturing PMI rose to 50.0 in October from 49.8 in September.
The ISM Manufacturing PMI fell to 46.7 in October versus 49 in the prior month, compared to market expectations of 49.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35509384/these-3-real-estate-stocks-delivering-high-dividend-yields-are-recommended-by-wall-stree"> These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>

U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve.
Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose 0.32% to 12,892.45. The S&amp;P 500 also rose, gaining, 0.15% to 4,199.94.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35508877/2-8m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying"> $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares jumped by 0.5% on Wednesday.
In trading on Wednesday, utilities shares fell by 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Cellectis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>) shares shot up 154% to $2.45. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.
Shares of Patriot Transportation Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pati#NASDAQ">PATI</a>) got a boost, shooting 105% to $15.75. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash.
Monopar Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnpr#NASDAQ">MNPR</a>) shares were also up, gaining 42% to $0.6383. Monopar presented data showing tumor reduction benefit of camsirubicin from ongoing Phase 1b in patients with advanced soft tissue sarcoma at the 2023 Connective Tissue Oncology Society Annual Meeting.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) shares dropped 50% to $1.1317 following reports that the company is nearing bankruptcy.
Shares of IRIDEX Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irix#NASDAQ">IRIX</a>) were down 45% to $1.82. Iridex has withdrawn its previously announced annual guidance for 2023 and plans to provide additional information during its third-quarter earnings release based on the information available at that time.
Paycom Software, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/payc#NYSE">PAYC</a>) was down, falling 37% to $154.05. Paycom Software reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35510705/top-3-consumer-stocks-that-could-sink-your-portfolio-in-q4"> Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 2.8% to $83.27 while gold traded up 0.1% at $1,996.10.
Silver traded down 0.3% to $22.885 on Wednesday while copper rose 0.5% to $3.6665.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 0.5%, London&rsquo;s FTSE 100 rose 0.4% while Spain&rsquo;s IBEX 35 Index rose 0.4% The German DAX gained 0.4% French CAC 40 climbed 0.4%, while Italy&rsquo;s FTSE MIB Index jumped 0.5%.
The S&amp;P Global/CIPS UK manufacturing PMI was revised lower to 44.8 in October from the preliminary reading of 45.2, while Nationwide House Price Index fell by 3.3% year-over-year in October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Wednesday, with Japan&rsquo;s Nikkei 225 rising 2.41%, Hong Kong&rsquo;s Hang Seng Index falling 0.06% and China&rsquo;s Shanghai Composite Index gaining 0.14%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, slipped around 0.4%.
Retail sales in Hong Kong surged 10.1% year-over-year in September versus a 11% increase in the prior month. The S&amp;P Global India manufacturing PMI fell to 55.5 in October from 57.5, while the Caixin China general manufacturing PMI declined to 49.5 in October from 50.6 in the previous month. The au Jibun Bank Japan manufacturing PMI was revised higher to 48.7 in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35509384/these-3-real-estate-stocks-delivering-high-dividend-yields-are-recommended-by-wall-stree"> These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>

US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected

<h3>Gainers</h3>
<ul>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) stock rose 171.1% to $2.63 during Wednesday's pre-market session. The company's market cap stands at $146.1 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock rose 79.3% to $0.77. The market value of their outstanding shares is at $10.9 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock rose 31.38% to $0.11. The company's market cap stands at $4.6 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) shares moved upwards by 24.96% to $9.66. The company's market cap stands at $1.4 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares moved upwards by 21.04% to $2.07. The company's market cap stands at $121.2 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares increased by 14.97% to $1.42. The market value of their outstanding shares is at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares fell 29.9% to $2.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $37.3 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares declined by 18.67% to $0.48. The market value of their outstanding shares is at $10.4 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock declined by 12.31% to $0.67. The company's market cap stands at $1.1 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock decreased by 11.82% to $1.46. The company's market cap stands at $75.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) stock decreased by 10.4% to $3.19. The company's market cap stands at $72.8 million. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares decreased by 8.21% to $0.75. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTL

PBLA

TSBX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Guidance

Health Care

Iridex Has Withdrawn Its Previously Announced Annual Guidance For 2023 And Plans To Provide Additional Information During Its Q3 Earnings Release Based On The Information Available At That Time

Iridex receives European patent on micropulse technology

Analysts who follow IRIDEX Corporation (IRIX) on average expect it to decline -27.27% over the next twelve months. Those same analysts give the stock an average rating of Hold. That average rating earns IRIDEX Corporation an Analyst Ranking of 5, which means it ranks higher than 5 of stocks, based on data compiled by Inves

Where Does Wall Street Think IRIDEX Corporation (IRIX) Stock Will Go?

Overall market sentiment has been down on IRIDEX Corp (IRIX)  stock lately. IRIX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. IRIDEX Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IRIX!See Full IRIX ReportWhat is Stock Sentiment?When

What is the Market's View on IRIDEX Corp (IRIX) Stock's Price and Volume Trends Tuesday?

Wall Street is positive on IRIDEX Corp (IRIX). On average, analysts give IRIX a Hold rating. The average price target is $2, which means analysts expect the stock to decrease by -27.80% over the next twelve months.That average ranking earns IRIX an Analyst Rating of 5, which is better than 5% of stocks based on data compil

IRIDEX Corp (IRIX) Stock: Do Analysts Think You Should Buy?

IRIDEX GAAP EPS of -$0.18 misses by $0.13, revenue of $12.5M misses by $2.4M

IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Iridex (NASDAQ:<a href="https://investorplace.com/stock-quotes/irix-stock-quote/">IRIX</a>) just reported results for the fourth quarter of 2023.<ul><li>Iridex reported earnings per share of -18 cents. This was below the analyst estimate for EPS of -5 cents.</li><li>The company reported revenue of $12.46 million.</li><li>This was 16.39% worse than the analyst estimate for revenue of $14.90 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/irix-stock-earnings-iridex-for-q4-of-2023/">IRIX Stock Earnings: Iridex Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IRIX Stock Earnings: Iridex Misses EPS, Misses Revenue for Q4 2023

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Iridex (IRIX – Research Repor...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)

Iridex Cp (IRIX) said after close Tuesday that it lost $0.18 per share in quarter four 2023. On the revenue line, the company reported $12.5 million, missing estimates by $2.4 million.In the same quarter a year ago, the company lost $0.07 per share on revenue of $15.2 million. The stock is up 16.73% to $2.93 after the repo

Iridex Cp Up 16.73% To $2.93 After Earnings Miss

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

ARGX

KROS

TOPCF

Press Releases

Iridex to Report Third Quarter Financial Results on November 14, 2023

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

Iridex Reports Third Quarter 2023 Financial Results and Business Update

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Legal

Iridex Corporation Receives European Patent on MicroPulse Technology

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024